Introduction
The hormone melatonin is produced primarily in the mammalian pineal gland and is released in a circadian manner, with low levels during the day and high levels at night (Tamarkin et al., 1985; Foulkes et al., 1997) . Melatonin has been implicated in numerous physiological processes, including the sleep-wake cycle, circadian entrainment, and seasonal reproduction (Reiter, 1980; Redman et al., 1983; Bartness et al., 1993; Slotten et al., 1999; Wyatt et al., 2006) . These effects are achieved by the binding of melatonin to specific receptors in the suprachiasmatic nucleus (SCN) of the hypothalamus (Zee and Manthena, 2007) and in the pars tuberalis (PT) of the pituitary (Morgan, 2000) .
Two high affinity melatonin receptor types, MT 1 and MT 2 , have been cloned in mammals: human, sheep, Siberian hamster, mouse, and rat (Reppert et al., 1994 (Reppert et al., , 1995 Weaver et al., 1996; Roca et al., 1996; Jin et al., 2003; Audinot et al., 2008) . The MT 1 and MT 2 melatonin receptors exhibit different molecular structure and chromosomal localization among these species. The human MT 1 and MT 2 melatonin receptors exhibit only 60% overall identity at the amino acid level, and show distinct binding profiles; the human MT 2 melatonin receptor has a lower affinity for 2-[ 125 I] iodomelatonin compared to the human MT 1 melatonin receptor (Reppert et al., 1995; Dubocovich et al., 1997; Audinot et al., 2003) . Both receptors belong to the family of G-protein-coupled receptors that are associated with the inhibition of adenylate cyclase (Reppert et al., 1994 (Reppert et al., , 1995 . Furthermore, activation of the MT 1 melatonin receptor induces a transient elevation in cytosolic calcium ions and inositol phosphate concentration, whereas activation of the MT 2 melatonin receptor inhibits the soluble guanylate cyclase pathway in MT 2 receptor-transfected cells (Brydon et al., 1999; Petit et al., 1999; MacKenzie et al., 2002) .
The expression of melatonin receptors has been studied in various tissues using expressed most abundantly in the SCN, and is also expressed in other regions of the brain (e.g., the paraventricular thalamus) and some peripheral tissues (e.g., the pituitary, kidney, and small intestine) (Reppert et al., 1994; Roca et al., 1996; Drew et al., 1998; Sallinen et al., 2005) . A targeted deletion of the MT 1 melatonin receptor in mice has been demonstrated to block the melatonin-induced inhibition of neuronal firing in SCN slices; however, the phase-shifting responses to melatonin were only slightly impaired (Liu et al., 1997) . The MT 2 receptor is expressed dominantly in the retina, and also in the SCN and hippocampus (Reppert et al., 1995; Liu et al., 1997; Dubocovich et al., 1998) . Activation of the MT 2 melatonin receptor phase-shifts the circadian rhythm of neuronal activity in the SCN and inhibits dopamine release in the retina (Dubocovich et al., 1997 (Dubocovich et al., , 1998 (Dubocovich et al., , 2005 .
Accumulating evidence suggests that melatonin can influence sleep-promoting and sleep-wake rhythm regulating action through MT 1 and MT 2 melatonin receptors. Although studies of the sleep-promoting effect of melatonin have not always yielded consistent results, melatonin and ramelteon have been shown to have sleep-promoting effects in cats , monkeys (Zhdanova et al., 2002; Yukuhiro et al., 2004) , and humans (Wyatt et al., 2006; Zammit et al., 2007) . Indeed, ramelteon has been approved in the US for the treatment of insomnia. In preclinical studies, monkeys may be the most suitable species for evaluating the sleep-promoting effect of melatonin receptor agonists.
This is because such an effect has been disputed in nocturnal animals, such as rats (Mailliet et al., 2001; Akanmu et al., 2004) . Decreases in sleep latency after the administration of melatonin receptor agonists has been demonstrated only in monkeys and humans. However, the pharmacological profiles of the monkey melatonin receptors remain to be determined.
Therefore, characterization of the monkey melatonin receptors is important for evaluation and interpretation of the sleep-promoting effect in monkeys. In this study, we cloned the This article has not been copyedited and formatted. The final version may differ from this version. 
Methods

Chemicals and Drugs
Ramelteon, (S)-N- [2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b] 
propionamide (TAK-375), was synthesized at Takeda Pharmaceutical Company, Ltd.
(Osaka, Japan) (Uchikawa et al., 2002 
Animals
Twelve adult (9 males and 3 females) cynomolgus monkeys (Macaca fascicularis) that weighed between 2.8 and 6.6 kg were cared for in accordance with the principles and guidelines of the Takeda experimental animal committee.
Genomic DNA and RNA isolation
The monkeys were anesthetized with ketamine and then sacrificed. Brain tissues (SCN, cerebral cortex, putamen, caudate nucleus, amygdala) and eyes were dissected immediately after obtaining coronal sections of the brains, frozen quickly in dry ice, and then stored at -80°C until use. Genomic DNA was isolated from brain tissue (putamen) using a QIAGEN Genomic-tip 100/G and a QIAGEN Proteinase K (QIAGEN, Valencia, CA) according to the manufacturer's protocol. Total RNA was extracted from brain tissues and eyes using Isogen (Nippon Gene, Tokyo, Japan), and then mRNA was isolated using a μMACS mRNA Isolation Kit (Miltenyi Biotec, Auburn, CA) according to the manufacturer's protocol.
Cloning of monkey MT 1 melatonin receptor cDNA
The coding region of monkey MT 1 melatonin receptor, which comprises two exons (exon 1 and exon 2), was obtained by nested PCR amplification of monkey genomic DNA using primers that anneal outside the coding region of each exon. The primer design was based on an alignment of the sequences of human MT 1 melatonin receptor cDNA and the rhesus The design of the specific primers for monkey MT 2 melatonin receptor was based on rhesus monkey genome data from the UCSC genome browser as well as on the monkey MT 1 melatonin receptor. Using MT2-F1/R1 or MT2-F2/R2 primers (Table 1) , the first and second PCR amplifications were carried out in a total volume of 25 µl containing 0.5 µl of Pfx50 DNA Polymerase, 2.5 µl of 10× Pfx50 PCR mix, 0.75 µl of 10 mM dNTPs, 2 µl of 3.75 µM each primer, and 2 µl of first strand cDNA or 1:400 dilution of the first-round PCR products under the conditions described in Table 1 .
DNA Sequencing
The final PCR products were purified using a QIAquick PCR Purification Kit (QIAGEN) and subcloned into a pCR-Blunt II-TOPO vector (Invitrogen). The clones were sequenced in both directions using a Big Dye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and an ABI Prism 3700 capillary sequencer.
Expression studies
The full-length monkey MT 1 melatonin receptor cDNA was subcloned into the expression vector pcDNA3.1 (Invitrogen). The myc peptide coding sequence was fused to the C terminus of full-length and variants of the monkey MT 2 receptor by PCR using primers containing a linker and the myc sequence:
5′-CTAGTAAACGGCATGGCATCAATGCAGAAGCTGATCTCAGAGGAGGACCTGTA G -3′. All plasmids were confirmed by sequencing analysis. CHO-K1 cells were cultured in Eagle's Minimum Essential Medium-α (MEM-α; Sigma-Aldrich) supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 μg/ml streptomycin ( 
Results
Cloning of the monkey MT 1 and MT 2 melatonin receptors
We initially cloned the monkey MT 1 and MT 2 melatonin receptors by nested PCR amplification of monkey SCN and eye mRNA-derived cDNAs, using exon 1-and exon 2-untranslated region primers based on an alignment of human melatonin receptor sequences and the rhesus monkey genome sequence. Although monkey MT 1 melatonin receptor was not amplified from monkey SCN-derived cDNA using the nested PCR approach, it was cloned from monkey genomic DNA (Fig. 1) . (Fig. 3) . All the variants contained nonsense mutations in the coding region of the deduced protein, and had only the first putative transmembrane domain.
Comparison of the amino acid sequences of MT 1 melatonin receptors revealed that the monkey MT 1 melatonin receptor has the highest amino acid homology with the human MT 1 melatonin receptor (95% identity) and has 85% and 84% identity to mouse and rat MT 1 melatonin receptor, respectively (Fig. 1) . Similarly, the monkey MT 2 melatonin receptor showed higher homology (96% identity) to the human MT 2 melatonin receptor compared with mouse or rat MT 2 melatonin receptor (Fig. 2) . The amino acid sequence of monkey melatonin receptors deduced from the rhesus monkey genome sequence was not fully identical to those of the cloned receptors (MT 1 : a methionine to isoleucine exchange at amino acid residue 203, MT 2 : an aspartate to asparagine exchange at amino acid residue 3).
Expression of the monkey MT 2 variant receptors in CHO-K1 cells
To determine whether the monkey MT 2 variant receptors have an ability to bind melatonin receptor ligand, their binding properties were examined using CHO-K1 cells transiently expressing the monkey MT 2 receptor or variant receptors. The full-length monkey MT 2 melatonin receptor showed high specific binding to 2-[ 125 I] iodomelatonin, whereas none of the variant receptors did (Fig. 4) . In order to confirm whether the variant receptors were indeed translated in CHO-K1 cells, a myc tag was fused to the C terminus of the full-length receptor (a positive control) and the variant receptors, and then their expression levels were assessed by western blot analysis. A diffuse band of an approximately 42-kDa protein representing myc-tagged full-length MT 2 receptor protein was expressed at a relatively high level (Fig. 5) . The diffuse patterns of the full-length MT 2 receptor and the human MT 1 receptor proteins might be attributable to protein glcosylation and high hydrophobicity (Brydon et al., 1999) . In contrast, myc-tagged variant receptor proteins (V1, V2, V3) were clearly detected only in the presence of the proteasome inhibitor MG-132 (Fig. 5) . Furthermore, two major bands were detected in the V3 variant lysates.
These results suggest that monkey MT 2 variant receptor proteins were rapidly degraded by proteasomes in CHO-K1 cells and also that the V3 variant receptor protein was cleaved by an unknown mechanism.
Binding of 2-[ 125 I] iodomelatonin to the recombinant and native monkey melatonin
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Competition by ramelteon and melatonin for 2-[ 125 I] iodomelatonin binding to the recombinant and native monkey melatonin receptors
We determined the affinities of ramelteon and melatonin for recombinant and native monkey melatonin receptors by performing competition binding experiments. Figure 7 illustrates the concentration-dependent inhibition of 2-[ 125 I] iodomelatonin binding to recombinant (Fig. 7A, 7B ) and native monkey melatonin receptors (Fig. 7C ) by ramelteon and melatonin (0.64 pM-10 nM). Ramelteon displayed 3-to 7-fold higher affinities for recombinant and native monkey melatonin receptors than melatonin, which is consistent with the results for human melatonin receptors (Table 2) . Nevertheless, although the affinity of ramelteon for monkey MT 1 melatonin receptor was comparable to that for human MT 1 melatonin receptor, its affinity for monkey MT 2 melatonin receptor was higher than that for human MT 2 melatonin receptor (K i = 14 ± 0.5 pM and 112 ± 5 pM for the human MT 1 and MT 2 melatonin receptors, respectively; Kato et al., 2005) .
Inhibition of PACAP27-stimulated cAMP production in CHO cells transiently coexpressing human PAC-1 with the monkey melatonin receptors.
In order to confirm that the recombinant monkey melatonin receptors are functionally coupled to adenylate cyclase, we examined the effects of ramelteon and melatonin on PACAP27-stimulated cAMP production in CHO-K1 cells transiently coexpressing human (von Gall et al., 2000) . Ramelteon and melatonin caused a dose-dependent inhibition of the cAMP production induced by PACAP27 (Fig. 8A, 8B ). For ramelteon, the IC 50 values (n = 3) were 28.5 ± 8.55 pM and 20.1 ± 9.25 pM for the monkey MT 1 and MT 2 receptors, respectively, whereas the corresponding values for melatonin were 274 ± 40.2 pM and 111 ± 24.6 pM. Thus, the agonist activity of ramelteon at monkey MT 1 and MT 2 receptors was 9.6 and 5.5 times more potent, respectively, than melatonin.
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Discussion
In this study, we characterized the cynomolgus monkey MT 1 and MT 2 melatonin receptors, and determined the in vitro activity of ramelteon at these receptors as compared with melatonin. Ramelteon displayed higher affinities than melatonin for monkey recombinant and native melatonin receptors; moreover, these affinities for monkey receptors were comparable to those for human receptors ( Fig. 2 ; Kato et al., 2005) .
Furthermore, ramelteon inhibited PACAP27-induced cAMP production with a higher potency than melatonin. These observations indicate that the pharmacological profiles of the monkey melatonin receptors are similar to those of the human melatonin receptors.
We initially cloned the novel genes for cynomolgus monkey MT 1 and MT 2 melatonin receptors, and also three MT 2 splice variants. The monkey MT 1 and MT 2 melatonin receptors had significant amino acid homology with the human MT 1 and MT 2 melatonin receptors, i.e., 95% and 96% identity, respectively. In addition, the monkey melatonin receptors showed high amino acid homology with rat (84% for MT 1, 80% for MT 2, respectively) and mouse homologues (85% for MT 1, 80% for MT 2, respectively). receptor genes contain a conserved intron splice site in the first cytoplasmic loop. This intron could lead to alternative splicing forms of these receptors (Reppert et al., 1995) .
Indeed, Slominski et al. (2003) reported that the human MT 2 variant receptor had an insertion of 154 bp from intron 1 and lacked a 200 bp from exon 2, which generated a frameshift and premature translation termination; the resultant truncated protein consisted of 73 N-terminal amino acids. The Siberian hamster MT 2 receptor lacks exon 1, and also has two nonsense mutations in the coding region . Similar to the monkey MT 2 variant receptors, it is unlikely that such variants are functional.
We iodomelatonin binding in the monkey SCN may be due to the presence of the MT 1 melatonin receptor (Liu et al., 1997; Dubocovich et al., 1998) . example, ramelteon exhibited a 3.2-fold higher affinity and 5.5-fold higher potency than melatonin at the monkey MT 2 melatonin receptor. In contrast, the relative potency of ramelteon and melatonin at the human MT 2 melatonin receptor differs considerably from that predicted by binding activity (Kato et al., 2005) . Melatonin has a 17-fold lower potency than ramelteon compared with a 3.4-fold lower affinity at the human MT 2 receptor. The species differences in MT 2 melatonin receptor sequence may be involved in this phenomenon.
In conclusion, this study provides new information on the characters of native and recombinant monkey melatonin receptors. Similar to human homologues, ramelteon exhibited higher binding affinities and more potent functional activities than melatonin at monkey melatonin receptors. This information on monkey melatonin receptors will help us to gain an understanding of the pharmacological effects (e.g., sleep promotion) of melatonin receptor agonists in monkeys. In addition, the sequence and functional similarities between the melatonin receptors of monkeys and humans suggest that an evaluation of sleep-promoting effect of melatonin receptor agonists in monkeys may be useful for Table 2 . 
